| First Author | Rossignol J | Year | 2022 |
| Journal | iScience | Volume | 25 |
| Issue | 6 | Pages | 104353 |
| PubMed ID | 35874918 | Mgi Jnum | J:332856 |
| Mgi Id | MGI:7430871 | Doi | 10.1016/j.isci.2022.104353 |
| Citation | Rossignol J, et al. (2022) Neuropilin-1 cooperates with PD-1 in CD8(+) T cells predicting outcomes in melanoma patients treated with anti-PD1. iScience 25(6):104353 |
| abstractText | Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by restoring antitumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Neuropilin-1 (NRP1) is a transmembrane glycoprotein required for nervous system and angiogenesis embryonic development, also expressed in immune cells. We hypothesized that NRP1 could be an immune checkpoint co-receptor modulating CD8(+) T cells activity in the context of the antitumor immune response. Here, we show that NRP1 is recruited in the cytolytic synapse of PD1(+)CD8(+) T cells, cooperates and enhances PD-1 activity. In mice, CD8(+) T cells specific deletion of Nrp1 improves anti-PD1 antibody antitumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8(+) T cells predicts poor outcome of patients treated with anti-PD1. NRP1 is a promising target to overcome resistance to anti-PD1 therapies. |
